<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793450</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI362D102</org_study_id>
    <nct_id>NCT05793450</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment</brief_title>
  <official_title>Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how fast IBI362 gets into the blood stream and how&#xD;
      long it takes the body to remove it in participants with impaired kidney function compared to&#xD;
      healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 7, 2023</start_date>
  <completion_date type="Anticipated">October 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 13, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362</measure>
    <time_frame>Predose through 1344 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362</measure>
    <time_frame>Predose through 1344 hours postdose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>IBI362 - Mild and Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - IBI362 administered SC to participants with mild and moderate renal impairment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 - Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 - IBI362 administered subcutaneously (SC) to healthy participants with normal renal function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 - Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 - IBI362 administered SC to participants with severe renal impairment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362</intervention_name>
    <description>2.0mg, SC, single dose</description>
    <arm_group_label>IBI362 - Healthy</arm_group_label>
    <arm_group_label>IBI362 - Mild and Moderate Renal Impairment</arm_group_label>
    <arm_group_label>IBI362 - Severe Renal Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Participants:&#xD;
&#xD;
             o The weight of male subjects is not less than 50 kg, and the body weight of female&#xD;
             subjects is not less than 45 kg, and the body mass index (BMI) is within the range of&#xD;
             20~30 kilograms per meter squared (kg/m²), inclusive, at screening&#xD;
&#xD;
          -  Healthy Participants:&#xD;
&#xD;
             -- Healthy males or females as determined by medical history, physical examination,&#xD;
             and other screening procedures, with normal renal function, assessed by estimated&#xD;
             glomerular filtration rate (eGFR) ≥90 milliliters per minute (mL/min) at screening&#xD;
&#xD;
          -  Participants with Renal Impairment:&#xD;
&#xD;
               -  Males or females with stable mild to severe renal impairment, assessed by eGFR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All Participants:&#xD;
&#xD;
               -  Pregnant or lactating women, or men or women who are of childbearing potential&#xD;
                  and are not willing to use contraception within 6 months from the screening&#xD;
                  period to the administration of the study drug&#xD;
&#xD;
               -  Have known allergies to IBI362 or related compounds&#xD;
&#xD;
               -  Have a personal or family history of medullary thyroid carcinoma or have multiple&#xD;
                  endocrine neoplasia syndrome type 2&#xD;
&#xD;
               -  Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&#xD;
                  &gt;1.5× the upper limit of normal (ULN) or total bilirubin (TBL) &gt;1× ULN&#xD;
&#xD;
               -  Severe gastrointestinal diseases (such as active ulcer, pyloric obstruction,&#xD;
                  inflammatory bowel disease, etc.) occurred within 6 months before screening, or&#xD;
                  received gastrointestinal surgery or long-term use of drugs that directly affect&#xD;
                  gastrointestinal motility due to chronic gastrointestinal diseases&#xD;
&#xD;
               -  Have a history of acute and chronic pancreatitis, or serum amylase and/or lipase&#xD;
                  ≥ 1.5× ULN at screening, or fasting Triglyceride ≥ 5.64 mmol/L (500 mg/dl)&#xD;
&#xD;
          -  Participants with Renal Impairment:&#xD;
&#xD;
               -  obstructive urinary tract diseases (such as urinary stones, urinary tract&#xD;
                  obstruction caused by abdominal space-occupying lesions, etc.) or renal&#xD;
                  dysfunction caused by special types of renal parenchymal damage (such as&#xD;
                  polycystic kidney, medullary sponge kidney, Renal tumors, etc.) and/or patients&#xD;
                  with renal impairment who have diseases that are not related to renal disease but&#xD;
                  can cause renal impairment (eg, renal artery stenosis, acute drug injury, severe&#xD;
                  infection, hypovolemia, heart failure, etc.).&#xD;
&#xD;
               -  Have a history of kidney transplant&#xD;
&#xD;
               -  The treatment medication and/or the treatment medication of other comorbid&#xD;
                  diseases have been taken stably for less than 1 month at screening, or there are&#xD;
                  new medications within 1 month before screening (except temporary or intermittent&#xD;
                  use of drugs, such as Erythropoietin once a month, or diuretics as needed, etc.),&#xD;
                  or received any drug known to alter renal tubular creatinine secretion within 14&#xD;
                  days or 5 half-lives before screening, such as cimetidine D, trimethoprim or&#xD;
                  cibenzoline, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Yu</last_name>
    <phone>0512-69566088</phone>
    <email>yang.yu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aerospace Center Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jin Wang</last_name>
      <phone>010-59971772</phone>
      <email>wjlsq@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

